• 1
    Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation. Qual. Life Res. 1997; 6: 2126.
  • 2
    Lehman AF. A quality of life interview for the chronically mentally ill. Eval. Program Plann. 1998; 11: 5162.
  • 3
    Meltzer HY. Dimensions of outcome with clozapine. Br. J. Psychiatry Suppl. 1992; 17 (Suppl.17): 4653.
  • 4
    Meltzer HY. Outcome in schizophrenia: Beyond symptom reduction. J. Clin. Psychiatry 1999; 60: 37.
  • 5
    Voruganti L, Heslegrave R, Awad AG et al. Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability. Psychol. Med. 1998; 28: 165172.
  • 6
    Dickerson FB, Ringel NB, Parente F. Subjective quality of life in out-patients with schizophrenia: Clinical and utilization correlates. Acta Psychiatr. Scand. 1998; 98: 124127.
  • 7
    Fitzgerald PB, Williams CL, Corteling N et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr. Scand. 2001; 103: 387392.
  • 8
    Huppert JD, Weiss KA, Lim R et al. Quality of life in schizophrenia: Contributions of anxiety and depression. Schizophr. Res. 2001; 51: 171180.
  • 9
    Reine G, Lancon C, Di Tucci S et al. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr. Scand. 2003; 108: 297303.
  • 10
    Tomotake M, Kaneda Y, Iga J et al. Subjective and objective measures of quality of life have different predictors for people with schizophrenia. Psychol. Rep. 2006; 99: 477487.
  • 11
    Aki H, Tomotake M, Kaneda Y et al. Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophrenia. Psychiatry Res. 2008; 158: 1925.
  • 12
    Norman RMG, Malla AK, Mclean T et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr. Scand. 2000; 102: 303309.
  • 13
    Strejilevich SA, Palatnik A, Avila R et al. Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics. Psychiatry Res. 2005; 133: 277280.
  • 14
    Browne S, Roe M, Lane A et al. Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr. Scand. 1996; 94: 118124.
  • 15
    Browne S, Garavan J, Gervin M et al. Quality of life in schizophrenia: Insight and subjective response to neuroleptics. J. Nerv. Ment. Dis. 1998; 186: 7478.
  • 16
    Caron J, Mercier C, Diaz P et al. Socio-demographic and clinical predictors of quality of life in patients with schizophrenia or schizo-affective disorder. Psychiatry Res. 2005; 137: 203213.
  • 17
    Voruganti L, Cortese L, Oyewumi L et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr. Res. 2000; 16: 135145.
  • 18
    Davis JM, Chen N, Glick ID et al. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 2003; 60: 553564.
  • 19
    Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 1996; 153: 321330.
  • 20
    Breier A, Schreiber JL, Dyer J et al. National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome. Arch. Gen. Psychiatry 1991; 48: 239246.
  • 21
    Ho BC, Nopoulos P, Flaum M et al. Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life. Am. J. Psychiatry 1998; 155: 11961201.
  • 22
    Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999; 25: 233255.
  • 23
    Meltzer HY, Thompson PA, Lee MA et al. Neuropsychologic deficits in schizophrenia: Relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 1996; 14 (Suppl. 3): S27S33.
  • 24
    Velligan DI, Mahurin RK, Diamond PL et al. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr. Res. 1997; 25: 2131.
  • 25
    Heaton RK, Chelune GJ, Lehman RA. Using neuropsychological and personality tests to assess the likelihood of patient employment. J. Nerv. Ment. Dis. 1978; 166: 408416.
  • 26
    McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr. Res. 2000; 45: 175184.
  • 27
    Wilkinson G, Hesdon B, Wild D et al. Self-report quality of life measure for people with schizophrenia: The SQLS. Br. J. Psychiatry 2000; 177: 4246.
  • 28
    Kaneda Y, Fujii A, Ohmori T. Schizophrenia Quality of Life Scale: Validation of the Japanese version. Psychiatry Res. 2002; 113: 107113.
  • 29
    Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984; 10: 388398.
  • 30
    Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale. Seiwa Pub., Tokyo, 2001.
  • 31
    Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987; 13: 261276.
  • 32
    Bell MD, Lysaker PH, Beam-Goulet JL. Five-component model of schizophrenia: Assessing the factorial invariance of the positive and negative syndrome scale. Psychiatry Res. 1994; 52: 295303.
  • 33
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press, Washington, DC, 1994.
  • 34
    Inada T. Evaluation and Diagnosis of Drug–Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to Its Usage. Seiwa Pub, Tokyo, 1996 (in Japanese).
  • 35
    Kaneda Y, Fujii A, Ohmori T. Psychometric properties of the Japanese version of the Calgary Depression Scale for Schizophrenics. J. Nerv. Ment. Dis. 2000; 188: 237239.
  • 36
    Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part 4. Dose equivalence of novel antipsychotics: Aripiprazole. Jpn. J. Clin. Psychopharmacol. 2006; 9: 249258 (in Japanese).
  • 37
    Ritsner M, Modai I, Endicott J. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J. Clin. Psychiatry 2000; 61: 880889.
  • 38
    Bell MD, Lysaker PH, Milstein RM et al. Concurrent validity of the cognitive component of schizophrenia: Relationship of PANSS scores to neuropsychological assessments. Psychiatry Res. 1994; 54: 5158.
  • 39
    Hofer A, Rettenbacher MA, Widschwendter CG et al. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2006; 256: 246255.
  • 40
    Hofer A, Niedermayer B, Kemmler G et al. Cognitive impairment in schizophrenia: Clinical ratings are not a suitable alternative to neuropsychological testing. Schizophr. Res. 2006; 92: 126131.
  • 41
    Keefe RSE, Goldberg TE, Harvey PD et al. The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004; 68: 283297.
  • 42
    Karow A, Moritz S, Lambert M et al. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005; 38: 320326.
  • 43
    Taniguchi T, Sumitani S, Aono M et al. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms. Hum. Psychopharmacol. 2006; 21: 439445.
  • 44
    Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006; 63: 10791087.